KUALA LUMPUR, Malaysia, Aug. 4, 2026 /PRNewswire/ — Hyatt Regency Kuala Lumpur at KL Midtown has been honoured with a Commendation (Hospitality) at the Malaysian Institute of Architects (PAM) Awards, recognising its contemporary design inspired by Malaysian influences. Designed by world-renowned Japanese architect Kengo Kuma, the hotel reflects a harmonious blend of nature, Japanese craftsmanship and local cultural elements, creating a refined urban sanctuary in the heart of Kuala Lumpur.

Opened in August 2025, the hotel is strategically located within the emerging KL Midtown precinct and the vibrant Dutamas–Mont Kiara corridor, offering seamless access to the Malaysia International Trade and Exhibition Centre (MITEC), MATRADE and one of the city’s fastest-growing business and lifestyle districts. Combining award-winning design with thoughtful hospitality, Hyatt Regency Kuala Lumpur at KL Midtown is an ideal destination for business, leisure and extended-stay travellers.

Award-Winning Architecture by Kengo Kuma

Guided by Kuma’s philosophy of ma, the thoughtful use of space, the interiors embrace natural light, airy layouts and a seamless connection with nature. Malaysian-inspired textiles, motifs and handcrafted rattan elements by local artisans further enrich the design, creating a refined sense of place that celebrates both local heritage and contemporary hospitality.

Thoughtfully Designed Rooms, Residences and Wellness Facilities

Hyatt Regency Kuala Lumpur at KL Midtown offers 406 contemporary accommodations across 15 room categories, comprising 306 guestrooms and suites and 100 fully serviced residences. Designed for business, leisure and extended stays, the residences feature one- and two-bedroom layouts with fully equipped kitchenettes with full-size fridge and freezer, washing machine with dryer, separate living and dining areas and modern home comforts for effortless long-term living.

Guests staying in Regency Club rooms enjoy exclusive access to the Regency Club Lounge on the 21st floor, offering panoramic city views, all-day refreshments and evening cocktails in an elegant setting.

The hotel’s wellness and recreation facilities include two infinity pools, an exclusive adults’ pool for Regency Club and serviced residence guests, and a family-friendly pool with a jacuzzi, as well as Core Fitness Centre, one of the city’s largest hotel gyms, complemented by sauna and steam facilities. Families are also well catered for with a dedicated Kidz Club, offering engaging activities for younger guests in a safe and welcoming environment.

A Premier Destination for Meetings and Events

Positioned directly opposite Asia’s largest convention centre, the Malaysia International Trade and Exhibition Centre (MITEC), Hyatt Regency Kuala Lumpur at KL Midtown is ideally positioned to support international exhibitions, conventions and corporate events. As a natural extension of Malaysia’s largest exhibition venue, the hotel offers seamless connectivity for delegates and event organisers alike.

The hotel features 16 flexible function spaces spanning over 27,000 square feet, including the elegant pillarless Regency Ballroom, which accommodates 600 guests for banquets. Designed with abundant natural light, contemporary interiors and warm wood finishes, the venues provide an inspiring setting for meetings, conferences, weddings and social celebrations. Complemented by a zen-inspired outdoor courtyard, dedicated event concierge services and in-house audiovisual expertise, Hyatt Regency Kuala Lumpur at KL Midtown delivers a seamless and elevated event experience.

Culinary Excellence for Every Occasion

Hyatt Regency Kuala Lumpur at KL Midtown offers a distinctive culinary journey across four dining concepts, reflecting Hyatt’s commitment to authentic flavours, thoughtful sourcing and exceptional craftsmanship.

“Our culinary philosophy is rooted in authenticity and responsibility,” said Jonas Juchli, Executive Chef. “We celebrate Malaysia’s rich culinary heritage while preserving time-honoured techniques and using thoughtfully sourced ingredients. Together with our talented team of chefs, we create dining experiences that honour tradition while embracing contemporary innovation.”

The hotel’s signature venues include Midtown Brasserie, serving Malaysian favourites alongside Asian and Western classics; Midtown Lounge, offering artisanal pastries, premium teas and light refreshments; ENSŌ Izakaya & Bar, a vibrant Japanese dining destination featuring premium seafood, authentic izakaya fare, and handcrafted cocktails; and China House, where regional Chinese cuisine takes centre stage with specialties including its signature wood-fired Peking Duck, handcrafted dim sum, and premium seafood.

Complementing its restaurants, Hyatt Regency Kuala Lumpur at KL Midtown also offers certified halal banquet dining led by Executive Chef Jonas Juchli, with bespoke menus spanning Malaysian, Chinese, Japanese, and international cuisines. Combined with its versatile event spaces, the hotel’s culinary expertise delivers memorable dining experiences for meetings, celebrations and social occasions.

A Commitment to Sustainability

Reflecting modern corporate values, the hotel has achieved GreenRe Gold certification, incorporating eco-conscious principles from the early planning phases.

“A proven commitment to sustainability is critical for today’s MICE clients,” General Manager Till Martin noted. “Our eco-conscious principles were integrated during the pre-construction planning phase. This holistic approach ensures we deliver both exceptional events and environmental responsibility.”

Anchoring the future of KL Midtown

As KL Midtown continues to develop as a mixed-use destination with hospitality, offices, retail, urban park, leisure and residential components, Hyatt Regency Kuala Lumpur at KL Midtown is well placed to become a central hospitality anchor for the precinct. The wider development is positioned as a one-stop destination offering hotel, office, retail, leisure and residential options at a single address, strengthening the hotel’s role as both a business and lifestyle hub.

Other Awards & Recognition

In addition, the hotel’s dining concepts have been recognised at the HAPA Awards 2026, with China House named Best Chinese Restaurant and ENSŌ Izakaya & Bar awarded Best Bar, alongside individual accolades for Top Executive Chef, Top Executive Chinese Chef and Top Mixologist.

Hyatt Regency KL Midtown

No 7 Jalan Dutamas 2, 50480 Kuala Lumpur, Malaysia

Website: Hyatt Regency KL Midtown

eShop: Hotel eShop 

Instagram: @hyattregencyklmidtown, @chinahouse_kualalumpur @enso.izakaya.kl

About Hyatt Regency Kuala Lumpur at KL Midtown

Nestled at 7 Jalan Dutamas 2 within the dynamic KL Midtown district, Hyatt Regency Kuala Lumpur at KL Midtown enjoys an enviable location in the vibrant heart of Dutamas and Mont Kiara. Designed by world-renowned Japanese architect Kengo Kuma, the hotel embodies a harmonious fusion of nature, Malaysian artistry, and contemporary sophistication.

The property offers a total of 406 accommodations, comprising 306 well-appointed guestrooms and suites, together with 100 fully serviced residences—seamlessly catering to both short-term visitors and extended-stay guests. For events and meetings, the hotel features 16 flexible function rooms equipped with state-of-the-art facilities, including a spectacular pillarless ballroom and meeting spaces spanning three floors. The banquet facilities are also halal-certified.  Dining options at the hotel include ENSO Izakaya & Bar, China House, Midtown Brasserie, and Midtown Lounge. For more information, please visit www.hyattregencyklmidtown.com.

Experienced Healthcare Executive to Lead Masimo’s Next Chapter of 
Innovation and Growth as a Danaher Company

IRVINE, Calif., Aug. 4, 2026 /PRNewswire/ — Masimo, a Danaher company and a specialty diagnostics solutions innovator of pulse oximetry and other patient monitoring solutions, today announced the appointment of Tim Benner as President, effective August 3, 2026.

Since joining Masimo in June 2025, Benner has played a key role in shaping the company’s strategy, strengthening customer relationships and guiding the business through its transition following Danaher’s acquisition of Masimo. He has served as Masimo’s Chief Marketing and Strategy Officer, and most recently as Chief Commercial Officer, leading the company’s global commercial organization, marketing, strategic growth initiatives and customer engagement efforts. His appointment reflects the confidence of both Masimo and Danaher leadership in his ability to lead the company through its next chapter of growth and innovation.

“Tim is a strong and experienced Masimo leader and has played an integral role in positioning the company for long-term success,” said Julie Sawyer Montgomery, CEO Designate, Danaher Corporation. “His strategic leadership, deep understanding of customers and commitment to innovation make him the right leader for Masimo’s next chapter as a Danaher company.”

Benner brings more than 30 years of executive leadership experience in the medical technology industry, including senior leadership roles at Edwards Lifesciences, Abbott, Terumo, Inari Medical/Stryker and most recently Masimo. Throughout his career, he has built high-performing organizations, driven commercial excellence and helped bring innovative healthcare technologies to clinicians and patients around the world.

“It is an honor to serve as President of Masimo,” said Tim Benner, President, Masimo. “For more than three decades, Masimo has earned the trust of clinicians around the world by developing breakthrough technologies that improve patient care. As a Danaher company, we have an incredible opportunity to build on that legacy by combining Masimo’s spirit of innovation with the power of the Danaher Business System. I look forward to working alongside our talented associates and our customers as we continue delivering meaningful innovations that help improve outcomes for patients around the world.”

As President, Benner will lead Masimo’s global business, with responsibility for driving innovation across the company’s patient monitoring portfolio, strengthening customer partnerships, accelerating commercial growth and advancing Masimo’s mission to improve patient outcomes through breakthrough technologies.

About Masimo 
Masimo, a Danaher company and a specialty diagnostics solutions innovator of pulse oximetry and other patient monitoring solutions, develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is for our innovations to empower clinicians to transform patient care. Masimo SET^® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown to outperform other pulse oximetry technologies in over 100 independent and objective studies, which can be found at www.masimo.com/evidence/featured-studies/feature. Masimo SET^® is estimated to be used on more than 200 million patients around the world each year and is the primary pulse oximetry at all 10 top U.S. hospitals as ranked in the 2026 Newsweek World’s Best Hospitals listing. Additional information about Masimo and its products may be found at www.masimo.com. 

About Danaher 
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve many of their most complex scientific and clinical challenges—helping move innovations from discovery to delivery faster for patients who depend on them. Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our more than 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow. Explore more at www.danaher.com.

Media Contact:
Christine McCullough
christine.mccullough@masimo.com

At the Precision Oncology Academy 2026, leading international experts explored how insights from tumour DNA and RNA can reveal treatment opportunities, explain drug resistance, and translate into more confident treatment decisions to improve cancer care.

KUALA LUMPUR, Malaysia, Aug. 4, 2026 /PRNewswire/ — Gene Solutions Malaysia hosted the Precision Oncology Academy 2026 on 25 July 2026 at the Sheraton Petaling Jaya Hotel under the theme ”Beyond Actionable”. An extension of the international K-CONNECT Platform and the recent K-CONNECT Summit 2026 in Vietnam, the Academy brought together oncology experts from the United Arab Emirates, Singapore, Malaysia, US and Vietnam. Through scientific lectures, multidisciplinary case discussions and interactive workshops, the programme addressed a central question: How can a deeper understanding of each patient’s cancer lead to more informed treatment decisions?

The Academy’s expert faculty was led by Chairperson Prof. Dr. Ho Gwo Fuang of Curie Oncology, Malaysia, and Co-chairperson Prof. Dr. Darren Lim Wan-Teck of the National Cancer Centre Singapore. They were joined by Prof. Dr. Shaheenah Dawood of Mediclinic Middle East, UAE; Dr. Christina Lai Nye Bing of Hospital Picaso, Malaysia; Dr. Katherine Teh Hooi Lay of Gleneagles Hospital Johor, Malaysia; Dr. Jenson Sow Wen Jen of Curie Oncology, Malaysia; Dr. Sinh Nguyen Duy and Dr. Lan Tu Ngoc Ly of Gene Solutions. Together, the faculty brought expertise spanning clinical oncology, cancer genomics, molecular diagnostics and genomic data interpretation, creating a multidisciplinary forum for translating complex molecular insights into practical clinical decisions.

Decoding the molecular story of cancer

Cancer is not defined solely by its site of origin in the body. Every tumour carries a complex molecular story, written in changes across its DNA and RNA. These changes influence how cancer develops, how it responds to treatment and how it may become resistant over time.

The Academy examined how large genomic and transcriptomic panels comprehensive profiling can provide a broader view of tumour biology. This includes comprehensive multi-omic approaches such as K-4CARE, which combines tissue-based DNA and RNA profiling with liquid biopsy circulating tumour DNA (ctDNA) analysis for both molecular profiling and ongoing monitoring. DNA profiling may identify genomic alterations associated with cancer growth and reveal biomarkers linked to targeted therapies, immunotherapies or clinical trials. RNA analysis can detect clinically important gene fusions and splice variants that may be missed or remain unclear through DNA-only testing.

The discussions highlighted the complementary roles of tissue and liquid (plasma) next-generation sequencing. While tissue testing remains essential for initial diagnosis and detailed characterisation, liquid biopsy can capture a wider view of tumour heterogeneity and resistance, particularly at progression. Used together, the two approaches offer clinicians a more complete molecular picture to guide treatment decisions.

The value of tissue and liquid longitudinal molecular profiling was illustrated by Prof. Dr. Darren Lim, who presented a real-world case of a patient with ALK-positive lung cancer managed over several years with serial next-generation sequencing. The case illustrated how repeated molecular profiling — combining tissue and plasma testing — can reveal a broader resistance landscape and support sequential treatment decisions throughout a patient’s journey.

Together, DNA, RNA, and ctDNA insights can provide clinicians with a more comprehensive understanding of the tumour. Molecular testing does not guarantee an actionable finding or suitable treatment, but it may uncover important information that would otherwise remain unseen.

Following cancer as it evolves

The Academy also highlighted the growing role of liquid biopsy in providing a more dynamic and holistic view of cancer.

One of the Academy’s key international speakers, Prof. Dr. Shaheenah Dawood, shared clinical perspectives on the evolving role of minimal residual disease (MRD) and ctDNA monitoring across cancer types. Prof. Dr. Dawood also reviewed the latest ASCO and NCCN guideline updates on liquid biopsy.

While tissue biopsy examines tumour material obtained from a particular location at a particular point in time, liquid biopsy detects cancer-related signals, including ctDNA, in the blood and can be repeated with a single blood draw. Depending on the clinical context and available evidence, liquid biopsy may help clinicians monitor treatment response, investigate emerging resistance or detect molecular signs of MRD. Because it can be performed repeatedly over time, liquid biopsy also offers the potential to follow how a cancer changes throughout treatment.

“The future of cancer management is dynamic. Liquid biopsy enables continuous monitoring of tumour evolution, helping clinicians make earlier, more informed treatment decisions.” said Prof. Shaheenah Dawood.

From complex data to confident decisions

The speakers emphasized that precision oncology is not simply about testing more genes or generating more data. The real challenge is determining which findings are clinically meaningful for an individual patient.

Not every molecular alteration drives cancer, and not every detected alteration can guide treatment. When a potentially actionable biomarker is identified, clinicians must consider the strength of the supporting evidence, the cancer type, previous treatments, the patient’s overall condition, and the availability of appropriate therapies or clinical trials.

This is why genomic findings must be interpreted together with pathology, medical history, and multidisciplinary clinical expertise.

“Precision oncology is no longer just about generating genomic data. It is about translating genomic insights, including MRD and ctDNA, into confident clinical decisions that improve patient care.” said Prof. Ho Gwo Fuang who chaired the Academy.

Connecting regional knowledge with clinical practice

The Precision Oncology Academy followed the K-CONNECT Summit 2026 | AI & Multi-omics – Shifting Paradigms in the New Era of Early Cancer Detection and Precision Oncology, recently held in Vietnam.

K-CONNECT was established by Gene Solutions as an international platform for multidisciplinary exchange in cancer genomics, ctDNA, molecular residual disease monitoring, comprehensive genomic and transcriptomic profiling, artificial intelligence and precision medicine.

“The K-CONNECT Platform was created to foster collaboration across the region, while Precision Oncology Academy translates that collaboration into practical clinical learning. By bringing together leading experts and real-world evidence, we hope to empower clinicians to confidently integrate precision oncology into routine patient care.” said Lim Chiun Khee, Country Director, Gene Solutions Malaysia.

For patients and families, cancer genomics may appear complex, but its purpose is clear: to understand the disease more completely so that treatment decisions can become more precise.

Through the K-CONNECT Platform, K-CONNECT Summit and Precision Oncology Academy, Gene Solutions continues to connect scientific advancement with clinical practice, helping make the evolving possibilities of precision oncology more accessible to clinicians and, ultimately, more meaningful for patients.

About Gene Solutions

Gene Solutions is a global biotechnology company headquartered in Singapore with a mission to make advanced genomic solutions accessible and affordable. Leveraging next-generation sequencing, multi-omics and artificial intelligence, the company offers a portfolio of solutions across multi-cancer detection, precision oncology and reproductive health, including SPOT-MAS, K-TRACK and K-4CARE.

Gene Solutions operates CAP-accredited NGS laboratories and has delivered millions of genetic tests worldwide since 2017. For more information, visit www.genesolutions.com and follow Gene Solutions on LinkedIn, Facebook, and X (Twitter).

For inquiries, please contact pr@genesolutions.com

Five-day deployment drives card payment success to 85%, digital wallet success to 90% and several hundred thousand dollars in first-month GMV

SAN FRANCISCO, Aug. 4, 2026 /PRNewswire/ — As AI companies compete on models, features and user experience, payment infrastructure is becoming an increasingly important factor in whether global demand converts into revenue.

Subotiz, a subscriptions, checkout and compliance platform for AI, SaaS and digital businesses, today announced that it helped a fast-growing AI creative platform increase overall payment success by 42% after launching its global payment infrastructure in five business days.

Following deployment, card payment success stabilized at approximately 85%, while Apple Pay and Google Pay success rates reached as high as 90%. The platform also generated several hundred thousand dollars in gross merchandise value during its first month.

The AI company had built a competitive product and attracted users across multiple markets, but its payment experience was holding back growth. Failed transactions, limited local payment options and checkout friction were causing users to drop off before completing their subscriptions.

An internal review found that one competitor’s advantage was not stronger AI technology, but a smoother payment and subscription experience.

“We initially viewed payments as a back-end issue, but the data showed they were directly affecting conversion and our ability to compete,” said Michael W., Founder & CEO of the platform. “Subotiz delivered a complete solution in five days and continues to support us around the clock.”

Subotiz developed a tailored solution covering global card acceptance, digital wallets, multicurrency transactions, subscription management and regional payment optimization. KYC and KYB reviews ran in parallel with technical integration, significantly reducing the time required to go live.

After launch, Subotiz analyzed transaction and failed-payment data to identify conversion gaps by market and payment method. The findings were used to improve payment routing, prioritize local wallets and refine the checkout experience.

“AI companies can build products faster than ever, but monetization often becomes the next bottleneck,” said Adam Mawdesley, CRO at Subotiz. “Our goal is to remove payment complexity and help digital businesses convert more global demand into recurring revenue.”

About Subotiz

Subotiz is a next-generation payment and revenue infrastructure platform designed for global digital businesses. By combining payments, subscription management, usage-based billing, tax and compliance automation, and fraud prevention into a unified platform, Subotiz enables SaaS, AI, eCommerce, and platform businesses to scale globally with greater operational efficiency and revenue flexibility. Learn more at www.subotiz.com.

BUKIT MERTAJAM, Malaysia, Aug. 4, 2026 /PRNewswire/ — KPJ Healthcare Berhad (“KPJ Healthcare” or “the Group”) today launched its first Orthopaedic and Rheumatology Centre of Excellence (“CoE”) at KPJ Penang Specialist Hospital (“KPJ Penang”), marking the third CoE under the KPJ Health System (“KPJHS”). As Malaysia’s first private integrated academic health system, the Group continues to advance specialised musculoskeletal and joint care through the integration of Practice, Education, Research and Innovation.

Designed to support the management of complex conditions, the Orthopaedic and Rheumatology CoE integrates orthopaedic subspecialties, rheumatology and multidisciplinary expertise such as rehabilitation within a coordinated model of care. Bringing together consultations, diagnostic imaging, treatment rooms and advanced rehabilitation together on a single floor, the Centre provides a more seamless patient experience from diagnosis through rehabilitation and recovery. Comprehensive services include general orthopaedics, spine surgery, arthroplasty (joint replacement), arthroscopy and sports surgery, foot and ankle surgery, hand and microsurgery, paediatric orthopaedics, trauma and fracture management, rheumatology and pain services.

Its capabilities are further enhanced by AI-assisted robotic joint replacement surgery, computer-assisted navigation and minimally invasive surgical techniques, supporting greater surgical precision, improved mobility and faster functional recovery. Supporting these capabilities are tailored rehabilitation programmes, including post-spine surgery, post-sports injury and paediatric orthopaedic rehabilitation, supported by specialised technologies such as an anti-gravity treadmill.

YBhg. Datuk Syed Mohamed Syed Ibrahim, Chairman of the KPJHS Governing Council, Chairman of KPJ Healthcare University Sdn. Bhd. and President & Chief Executive of Johor Corporation (“JCorp”) said, “Our ambition for every Centre of Excellence in the KPJ Health System, including the one we launch today, is not that it should remain a Centre in perpetuity. Our ambition is for it to continue growing, strengthening its clinical, academic and research capabilities until, over time, it is elevated into an Institute: a destination in its clinical discipline, a generator of published evidence, a trainer of national and international leaders, and a partner sought after by industry, academia and governments. World-class in the fullest meaning of that phrase.”

The Orthopaedic and Rheumatology CoE builds on the establishment of the Heart & Lung Centre of Excellence at Johor Specialist Hospital and the Neuroscience & Stroke Centre of Excellence at Damansara Specialist Hospital 2, reinforcing KPJ Healthcare’s long-term strategy to establish 15 Centres of Excellence nationwide by 2030 under the KPJHS. Through its integrated hub model anchored by KPJ Penang Specialist Hospital together with KPJ Selangor Specialist Hospital, the Centre enables shared expertise, common clinical standards, coordinated research and multidisciplinary collaboration across the KPJ Health System, demonstrating how specialised care can be delivered through one integrated academic health system. This integrated approach also provides the platform to accelerate the convergence of artificial intelligence, genomics and value-based care in shaping the future of specialised healthcare delivery.

KPJ Penang is a 270-bed tertiary hospital supported by more than 50 resident consultants across over 20 medical specialties. The establishment of the Orthopaedic and Rheumatology CoE further strengthens the hospital’s role within the KPJHS. Through the Centre, patients benefit from greater access to advanced orthopaedic treatments that have demonstrated improved patient-reported outcomes and shorter hospital stays. Complementing these capabilities, KPJ Penang is also the first in the Northern Region to provide advanced wound care management and, in collaboration with KPJ Healthcare University, is developing Malaysia’s first AI-assisted remote telewound care programme.

About KPJ Healthcare Berhad 

KPJ Healthcare operates 30 hospitals across Malaysia and four Ambulatory Care Centres, serving 3.3 million patients annually with 1,491 medical consultants. Nineteen hospitals are accredited by MSQH and four by JCI. As Malaysia’s first private healthcare provider to establish an Academic Health System, KPJHS integrates practice, education and research & innovation to drive clinical excellence and patient experience. Beyond hospitals, KPJ Healthcare operates Klinik Waqaf An-Nur (KWAN) clinics, dialysis centres and mobile clinics nationwide, and offers more than 40 academic programmes at KPJ Healthcare University (KPJU). KPJ Healthcare has been a constituent of the Bursa Malaysia FTSE4Good Index since 2016.

The same genomic technology once limited to specialist programs is now accessible to anyone, paired with an AI platform built on over a decade of clinical data and a new multimillion-dollar collaboration with Insilico Medicine to predict disease before it begins.

SAN FRANCISCO, Aug. 4, 2026 /PRNewswire/ — Human Longevity, Inc. (HLI), a precision health and longevity technology company, today announced the availability of Genomics for All, a clinical-grade whole genome sequencing product priced at $599. The offering sequences all 6.4 billion base pairs of an individual’s DNA and delivers AI-interpreted results through the HLI app, with no clinic visit required.

Unlike consumer ancestry tests, which analyse less than 0.02% of the genome using SNP chip technology, Genomics for All sequences the entire genome at 30x clinical-grade depth, the coverage standard required for medically meaningful interpretation. The result is a fundamentally different class of information: one capable of identifying inherited disease risk across more than 10,000 genetic variants, flagging pharmacogenomic markers that affect how individuals respond to common medications including statins and GLP-1 receptor agonists, and screening for carrier status in hereditary conditions. The report also covers health-related traits across nutrition, metabolism, and exercise response.

A central feature of the product is its AI-powered re-analysis capability. Because the genome itself does not change, HLI re-analyses each client’s genomic data on an ongoing basis as new research is published, new disease-gene associations are identified, and clinical guidelines are updated. When a new clinically relevant finding emerges, HLI proactively alerts affected clients, often within 24 hours of publication. This transforms a one-time sequencing event into a continuously evolving health resource.

“Our founder Dr. Venter helped make it possible for humanity to read the human genome,” said Wei-Wu He, Ph.D., Chairman and CEO of Human Longevity. “With Genomics for All, we are continuing that vision by helping more people understand what their genome may mean for their long-term health. Our goal is not to replace physicians or make deterministic predictions, but to provide better information that can support more informed conversations, earlier awareness, and more personalised care.”

Genomics for All sits within a broader AI-driven platform that HLI has been building for over a decade. In May 2026, HLI announced the launch of Human Life Foundation Models, Inc. (HLFM), a dedicated AI entity developed in partnership with Insilico Medicine, a clinical-stage generative AI biotechnology company. The multimillion-dollar collaboration aims to develop what the companies describe as the industry’s first large-scale AI foundation model dedicated to longevity science, drawing on HLI’s multimodal clinical and genomic datasets collected across more than 10,000 clients to identify the biological mechanisms of aging and enable predictive healthcare.

Genomics for All is the entry-level offering in HLI’s broader suite of precision health programs, which also includes more comprehensive assessments combining advanced imaging, biomarker panels, and clinician-guided care. The scientific advisory board includes Nobel laureates Dr. Geoffrey Hinton and Dr. Michael Levitt.

Genomics for All is available now at humanlongevity.com/genomics for $599.

About Human Longevity, Inc.
Human Longevity, Inc. is a precision health company focused on helping individuals better understand and manage long-term health through genomics, AI-supported interpretation, advanced diagnostics, and clinician-guided care. Founded in 2013 by Dr. J. Craig Venter and other life sciences leaders, the company has invested approximately $600M in research and worked with more than 10,000 clients across its clinics in San Diego and San Francisco. HLI’s programs include Genomics for All, Executive Health, 100+ Care, and 100+ Concierge. For more information, visit www.humanlongevity.com.